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Translationally-controlled tumor protein (TCTP) plays a role in a number of cellular processes, but
there is limited information about its function in cell differentiation. Previous observations of a
twofold induction of TCTP mRNA during osteoclast differentiation prompted us to investigate its
involvement in osteoclast differentiation. The osteoclastogenicity of TCTP gradually expressed dur-
ing osteoclast differentiation was conﬁrmed in mouse and human cells using loss-of-function stud-
ies and TCTP heterogeneous mice and transgenic mice. Higher expression ratios of TCTP to p21 could
represent TCTP-mediated phenotypic induction of osteoclast differentiation accompanied by p21
down-regulation, attenuating the proliferation of osteoclast precursor cells.
 2014 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Highly conserved translationally-controlled tumor protein
(TCTP or TPT1) is ubiquitously and abundantly expressed in all
eukaryotic tissues, suggesting that it has a role in a number of
important cellular processes and may be a basic housekeeping pro-
tein. It is also called IgE-dependent histamine-releasing factor,
anti-apoptotic fortilin, and growth-related protein p23 depending
on its functional role [1–4]. Especially in view of its role in cell dif-
ferentiation, proteomic analysis revealed an association between
TCTP expression and differentiation of Caco-2 cells [5,6] anddown-regulation of TCTP after differentiation of mouse embryonic
stem cells [7]. Nonetheless, information about its functional
involvement in cell differentiation is limited.
Various cell differentiation pathways can regulate homeostasis
in the body, but abnormalities in these pathways can lead to disor-
ders. For examples, menopause represents one of the natural
events triggering changes in bone homeostasis. Bones are con-
stantly renewed through osteoblastic bone formation and osteo-
clastic bone resorption. This process, termed ‘bone remodeling’,
is important not only for achieving normal bone mass, but also
for mineral homeostasis. However, over-activation or increased
numbers of osteoclasts due to accelerated differentiation, includ-
ing that caused by estrogen deﬁciency, can trigger a decrease in
bone mineral density (BMD), thereby inducing several bone-
related diseases such as osteoporosis, rheumatoid arthritis, peri-
odontal disease, and tumor metastasis.
Macrophage colony-stimulating factor (M-CSF) and receptor
activator of nuclear factor-kB ligand (RANKL) are the key cytokines
that induce osteoclast differentiation (or osteoclastogenesis) via
several signaling molecules such as mitogen-activated protein
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entially expressed genes, the microarray analysis revealed, and the
real-time PCR conﬁrmed, a RANKL-mediated twofold induction of
TCTP mRNA during osteoclast differentiation (data not shown).
Since the RANKL-mediated induction of TCTP has not been previ-
ously reported and its functional involvement in osteoclast differ-
entiation has not yet been studied, the relevance of TCTP in
osteoclast differentiation was investigated and is reported here.
2. Materials and methods
2.1. Preparation of mouse osteoclast precursor cells and their
differentiation
Animals were cared for according to the guide for the Institu-
tional Animal Care and Use Committee of the Korea Research Insti-
tute of Chemical Technology (Protocol ID No. 7D-M1, Approved No.
2014-7D-04-02). Mouse bone marrow-derived macrophages
(BMMs) were obtained and differentiated into osteoclasts as
described previously [8]. Then, mature osteoclasts were visualized
by staining with tartrate-resistant acid phosphatase (TRAP), a bio-
marker of osteoclast differentiation. TRAP-positive multinucleated
osteoclast cells (MNC; nuclearP 3) were counted.
2.2. TCTP knockdown experiment
For TCTP knockdown, the pLKO.1-shTCTP plasmid was con-
structed by inserting the mouse TCTP cDNA (the following under-
lined basepairs) into pLKO.1 at AgeI and EcoRI restriction sites
(50-CCG GTG AAG GTA CCG AAA GCA CAG TAC TCG AGT ACT GTG
CTT TCG GTA CCT TCA TTT TTG-30), (30-ACT TCC ATG GCT TTC
GTG TCA TGA GCT CAT GAC ACG AAA GCC ATG GAA GTA AAA
ACT TAA-50) [9]. Generation of lentiviral shTCTP and infection of
BMMs were performed as previously described [8]. In brief, lentiv-
iral packaging was performed by transfecting HEK293FT cells with
control/shTCTP, D 8.9 and VSVG using Lipofectamine 2000 (Invit-
rogen™). Lentiviral supernatant was collected from the culture
media 2 days after transfection. BMMs were incubated with viral
supernatant in the presence of polybrene (10 lg/ml). After infec-
tion, BMMs were cultured overnight, detached using StemPro
Accutase Cell Dissociation Reagent (Invitrogen™), and further
cultured with M-CSF (30 ng/ml) and puromycin (2 lg/ml) for
2 days. Puromycin-resistant BMMs were used for down-regulation
of shTCTP.
2.3. Proliferation assay
BMMs and shTCTP-infected BMMs were plated in triplicate in
96-well plates at a density of 1  104 cells/well. Cells were then
incubated for 1–3 days in the presence of mouse M-CSF (30 ng/
ml) and mouse RANKL (10 ng/ml), and cell viability was measured
using CCK-8 according to the manufacturer’s protocol.
2.4. Western blotting
Western blotting analysis was performed as described previ-
ously [8]. Anti-TCTP antibody was made in rabbits after injection
of the recombinant full-length TCTP proteins. Antibodies against
actin, p21, CDK2, and HRP-conjugated secondary antibodies were
purchased from Santa Cruz Biotechnology.
2.5. TCTP knockout/transgenic mice
TCTP knockout (TCTP+/) and transgenic mice (TCTP-TG) were
generated as described previously. Brieﬂy, TCTP-TG were preparedusing the pCAGGS-TCTP cDNA that contains chicken b-actin pro-
moter and CMV-IE as previously described [10]. Mice heterozy-
gous for the deleted allele of TCTP, TCTP+/ were kindly
provided by Hsin-Fang Yang-Yen (Institute of Molecular Biology,
Academia Sinica, Taipei, Taiwan) [11]; after the construction and
electroporation of targeting vector into the R1 ES cells, the posi-
tive clones were transiently transfected with cytomegalovirus
promoter-driven Cre expression vector to get the subclones
either the ﬂoxed or deleted allele of TCTP. The ES cell clones
so obtained were microinjected into mouse blastocysts and were
backcrossed to generate TCTP+/ mice [11]. All animal studies
were performed according to the guidelines of the Institutional
Animal Ethics Committee of Ewha Womans University, Korea
(IACUC No. 2013-01-064).
2.6. Micro-computed tomography (CT) and histological analysis
Bone histomorphometric analyses were performed in Genoss
Co. (Korea) with a lCT scanner (SkyScan1173, Bruker Corporation)
and the images were obtained using DataViewer (SKYSCAN). All
histomorphometric parameters were described in accordance with
standard criteria [12]. Femurs were ﬁxed in 4% paraformaldehyde
in phosphate buffered saline (PBS) overnight, decalciﬁed in 12%
EDTA, hydrated, parafﬁn-embedded, sectioned, and stained with
hematoxylin and eosin (H&E) and TRAP solution kit (Sigma–
Aldrich).
2.7. Human bone marrow cell (hBMCs) cultures and their
differentiation
According to the Ethics Guidelines for Wonkwang University
Hospital, after approval by the Institutional Review Board (IRB;
201310-HRBR-014), hBMCs were isolated by density gradient cen-
trifugation using Ficoll Histopaque (Sigma–Aldrich) and cultured
with human M-CSF (50 ng/ml) for 3 days. hBMCs were incubated
for 7 days in the presence of human RANKL and human M-CSF
(50 ng/ml) to differentiate them into osteoclasts.
2.8. Statistical analysis
All quantitative values are presented as the mean ± standard
deviation (S.D.). Statistical differences were analyzed using Stu-
dent’s t-test. A value of P < 0.05 was considered statistically
signiﬁcant.
3. Results and discussion
3.1. TCTP induction during osteoclast differentiation
During differentiation of BMMs into osteoclasts, TCTP was
gradually induced by RANKL (Fig. 1A). In addition, because TCTP
did not affect the osteoblast differentiation in its in vitro gain-of-
function study (SI Fig. 1A–C) and in the in vivo condition of TCTP
deﬁciency (SI Fig. 1D and E), we focused to identify the func-
tional role of TCTP in osteoclast differentiation in the following
study.
3.2. shTCTP-mediated inhibition of osteoclast differentiation
To validate the functional involvement of TCTP in the process of
osteoclast differentiation, a loss-of-function study was carried out.
TCTP knockdown strongly attenuated the RANKL-mediated induc-
tion of TCTP protein levels (Fig. 1A). The RANKL-induced formation
of TRAP-positive multinucleated osteoclast cells (TRAP+-MNCs)
was signiﬁcantly inhibited by TCTP knockdown (Fig. 1B and C).
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Fig. 1. Osteoclastogenicity of TCTP and its relationshipwith p21. (A)Western blotting showing the effect of TCTP knockdown on the expression of TCTP, p21, and CDK2 proteins
during RANKL-mediated differentiation of BMMs into osteoclasts. Brieﬂy, BMMswere infectedwith lentiviruses encoding TCTP-speciﬁc shRNA (shTCTP) or pLKO.1 (Control) and
selected with puromycin (2 lg/ml) for 2 days. Infected BMMswere cultured in the presence of RANKL (10 ng/ml) for the indicated number of days (d) in the presence of M-CSF
(30 ng/ml) then the protein expression levels were analyzed. Actin was used as an internal control. (B and C) Effect of TCTP knockdown on RANKL-mediated differentiation of
BMMs into osteoclasts. Infected BMMs were cultured for 4 days in the presence of the indicated concentrations of RANKL and M-CSF (30 ng/ml). Cells were ﬁxed, stained with
TRAP solution, andphotographed. TRAP+-MNCswere counted. ⁄⁄⁄P < 0.001 (vs. the control). (D) Effect of TCTPknockdownon theproliferationofBMMs. Theeffect of shTCTPon the
proliferation rate of BMMs was evaluated by CCK-8 assay. ⁄P < 0.05; ⁄⁄P < 0.01; ⁄⁄⁄P < 0.001 (vs. the control). All experiments were performed in triplicate.
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cells
The shTCTP-mediated attenuation of RANKL-induced osteoclast
differentiation could be explained by the inhibitory activity of TCTP
knockdown on the proliferation of osteoclast precursor cells,
BMMs (Fig. 1D). The hypothesis that TCTP functions as an essential
factor for cell proliferation was clariﬁed in a knockout mouse study
[11]. Detailed experiments suggested that TCTP has a role as a con-
served mitotic growth integrator in animals and plants [13]. The
anti-proliferative activity of TCTP has also been reported in cancers
[14]. Taken together, osteoclastogenic TCTP could control the
growth of osteoclast precursor cells. Knockdown of TCTP inhibited
osteoclast differentiation by attenuating their normal growth rate.
3.4. shTCTP-mediated induction of p21 in osteoclast precursor cells
To elucidate the mechanism of TCTP in osteoclastogenesis,
changes in signaling molecules related to osteoclast differentiation
such as Akt and MAP kinases were evaluated in TCTP knockdown
cells, but no changes were observed (SI Fig. 2). The anti-prolifera-
tive activity of TCTP knockdown in BMMs (Fig. 1D) led us to iden-
tify proteins related to the proliferation/cell cycle of precursor cells
as well as TCTP. Through a literature search, two candidates were
identiﬁed; cyclin-dependent kinase inhibitor p21 encoded by
WAF1/CIP1, and p53. After the report showing p53-dependent
expression of p21 [15], the involvement of p21 in osteoclast differ-
entiation was reported in several studies showing the inhibitory
effect of p21 knockdown on the formation of osteoclasts [16,17].
Moreover, reciprocal repression between p53 and TCTP wasrecently reported [18]. Therefore, the involvement of p21 and/or
p53 in TCTP’s role in osteoclastogenesis was investigated. Interest-
ingly, a seesaw expression pattern between p21 and TCTP was
found (Fig. 1A). When shTCTP was transfected into BMMs, p21
expression was strongly induced but TCTP expression was
decreased. Moreover, although shTCTP-induced p21 was also
strongly decreased during RANKL-induced osteoclast differentia-
tion as shown in the controls, the higher expression ratio between
TCTP and p21 could represent phenotypic osteoclast differentiation
by increasing the number of TRAP+-MNCs (Fig. 1A and B). There-
fore, the shTCTP-mediated induction of p21 in BMMsmight explain
the shTCTP-mediated growth inhibition of BMMs and attenuation
of RANKL-induced osteoclast differentiation. Similar to our results
showing no changes in Akt or MAP kinases by TCTP knockdown,
p21 expression was not changed by inhibitors of Akt or p38 during
osteoclast differentiation [19]. These results suggested that p21 is
repressed depending on the level of RANKL-induced TCTP rather
than Akt or MAP kinases. Additionally, since the protein expression
levels of p21’s partner, CDK2 were not changed by shTCTP (Fig. 1A),
and since p53 protein was not detected in our systems (SI Fig. 3)
neither of these molecules were studied in subsequent
experiments.
3.5. Increased bone mass in TCTP heterozygous mice with decreased
numbers of osteoclasts
Since TCTP-null mice die in utero, the femurs of viable TCTP het-
erozygous (TCTP+/) mice were evaluated to characterize the
impact of TCTP deﬁciency on bone [11]. MicroCT analysis revealed
that the trabecular BMD, bone volume/tissue volume (BV/TV or
S.-W. Choi et al. / FEBS Letters 588 (2014) 4026–4031 4029bone volume fraction), and the number of trabeculae (Tb.N) in the
femur were signiﬁcantly increased, and trabecular separation
(Tb.Sp) was decreased in TCTP+/ mice suggesting increased bone
mass in the presence of TCTP deﬁciency (Fig. 2A and B). This sug-
gestion was conﬁrmed in H&E-stained and TRAP-stained histolog-
ical sections showing higher trabecular density and decreased
numbers of TRAP-stained osteoclasts in TCTP+/ mice (Fig. 2C).
When BMMs isolated from TCTP+/ mice were differentiated into
osteoclasts in the presence of RANKL, a lower expression ratio
between TCTP and p21 was observed (Fig. 2D). These results could
explain why the number of TRAP+-MNCs was signiﬁcantly
decreased when TCTP+/ BMMs were treated with RANKL (Fig. 2E,
F and SI Fig. 4). In addition, TCTP deﬁciency signiﬁcantly attenu-
ated the RANKL-induced mRNA expression of osteoclastogenesis-
related molecules such as nuclear factor of activated T cells (NFAT)
c1, TRAP, dendritic cell–speciﬁc transmembrane protein (DC-
STAMP), vacuolar ATPase V0 subunit d2 (ATP6v0d2), and matrix
metalloproteinase 9 (MMP-9) (SI Fig. 5). Also, due to the anti-
osteoclastogenic activity of TCTP deﬁciency, the areas of resorption
were signiﬁcantly smaller in TCTP+/ (SI Fig. 6).RANKL (ng/ml)
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numbers of osteoclasts
In contrast with TCTP+/ mice, the femurs from TCTP transgenic
(TCTP-TG) mice were osteoporotic (Fig. 3A). MicroCT analysis and
histological sections conﬁrmed decreased bone formation
(Fig. 3B) and an increased number of TRAP-stained osteoclasts in
TCTP-TG mice (Fig. 3C). When BMMs isolated from TCTP-TG mice
were differentiated into osteoclasts, a higher expression ratio
between TCTP and p21 was observed (Fig. 3D). These results could
explain why the number of TRAP+-MNCs were signiﬁcantly
increased when BMMs isolated from TCTP-TG mice were treated
with RANKL (Fig. 3E and F).
3.7. shTCTP-mediated inhibition of osteoclast differentiation in hBMCs
with p21 upregulation
The osteoclastogenicity of TCTP was conﬁrmed in hBMCs. Len-
tiviral infection of shTCTP into hBMCs resulted in a prominent
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the lower expression ratio between TCTP and p21 indicated a
lower number of TRAP+-MNCs. Conversely, the over-expression of
TCTP by adenoviral infection signiﬁcantly enhanced the RANKL-
induced formation of TRAP+-MNCs from hBMCs (SI Fig. 7).
4. Conclusion
TCTP was gradually expressed during osteoclast differentiation.
The osteoclastogenicity of TCTP was conﬁrmed in both animal
models and human cells. An higher expression ratio between TCTP
and p21 could represent TCTP-mediated induction of phenotypic
osteoclast differentiation while attenuating p21-mediated inhibi-tion of cell growth and/or the cell cycle. The hypothesis that the
TCTP-related expression or degradation of p21 to affect osteoclast
differentiation might be regulated by TCTP-controlled miRNAs,
TCTP binding partners such as E3 ligase or calciumwould be exam-
ined in the further study [20–23].Acknowledgements
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